Predictors of benefit from ICIs beyond progression included performance status (ECOG 0–1), early response (PR/SD), oligoprogression, and low systemic inflammation (e.g., mGPS in NSCLC, CRP in RCC). This evidence concerns the gene CRP and non-small cell lung carcinoma.